204 related articles for article (PubMed ID: 37012013)
1. Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B).
Sakai H; Tsurutani J; Ozaki Y; Ishiguro H; Nozawa K; Watanabe K; Maeda S; Yokoe T; Imamura CK; Matsumoto K; Iwasa T; Chiba Y; Takiguchi D; Takano T
BMJ Open; 2023 Apr; 13(4):e070304. PubMed ID: 37012013
[TBL] [Abstract][Full Text] [Related]
2. Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (JTOP-B).
Ozeki R; Iihara H; Shimokawa M; Hashimoto H; Abe M; Mukohara T; Bando H; Hayashi T; Kawazoe H; Komoda M; Yanai Takahashi T; Saito M
BMJ Open; 2022 Mar; 12(3):e058755. PubMed ID: 35236735
[TBL] [Abstract][Full Text] [Related]
3. Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients.
Iihara H; Shimokawa M; Abe M; Hayasaki Y; Fujita Y; Nagasawa Y; Sakurai M; Matsuoka R; Suzuki A; Morishige K
BMJ Open; 2019 Jan; 9(1):e024357. PubMed ID: 30782732
[TBL] [Abstract][Full Text] [Related]
4. Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy.
Minatogawa H; Izawa N; Kawaguchi T; Miyaji T; Shimomura K; Kazunori H; Iihara H; Ohno Y; Inada Y; Arioka H; Morita H; Hida N; Sugawara M; Katada C; Nawata S; Ishida H; Tsuboya A; Tsuda T; Yamaguchi T; Nakajima TE
BMJ Open; 2020 Dec; 10(12):e041737. PubMed ID: 33334838
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.
Sutherland A; Naessens K; Plugge E; Ware L; Head K; Burton MJ; Wee B
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD012555. PubMed ID: 30246876
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial.
Iihara H; Shimokawa M; Gomyo T; Fujita Y; Yoshida T; Funaguchi N; Minato K; Kaito D; Osawa T; Yamada M; Hirose C; Suzuki A; Ohno Y
BMJ Open; 2019 Jul; 9(7):e028056. PubMed ID: 31278102
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Hashimoto H; Abe M; Tokuyama O; Mizutani H; Uchitomi Y; Yamaguchi T; Hoshina Y; Sakata Y; Takahashi TY; Nakashima K; Nakao M; Takei D; Zenda S; Mizukami K; Iwasa S; Sakurai M; Yamamoto N; Ohe Y
Lancet Oncol; 2020 Feb; 21(2):242-249. PubMed ID: 31838011
[TBL] [Abstract][Full Text] [Related]
9. Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).
Mersiades AJ; Tognela A; Haber PS; Stockler M; Lintzeris N; Simes J; McGregor I; Olver I; Allsop DJ; Gedye C; Kirby AC; Morton RL; Fox P; Clarke S; Briscoe K; Aghmesheh M; Wong N; Walsh A; Hahn C; Grimison P
BMJ Open; 2018 Sep; 8(9):e020745. PubMed ID: 30209152
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Vimolchalao V; Sakdejayont S; Wongchanapai P; Sukprakun S; Angspatt P; Thawinwisan W; Chenaksara P; Sriuranpong V; Vinayanuwatikun C; Parinyanitikun N; Poovorawan N; Tanasanvimon S
Int J Clin Oncol; 2020 Feb; 25(2):396-402. PubMed ID: 31776732
[TBL] [Abstract][Full Text] [Related]
11. Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy.
Hashimoto H; Abe M; Yanai T; Yamaguchi T; Zenda S; Uchitomi Y; Fukuda H; Mori M; Iwasa S; Yamamoto N; Ohe Y
Jpn J Clin Oncol; 2018 Oct; 48(10):950-952. PubMed ID: 30124989
[TBL] [Abstract][Full Text] [Related]
12. Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial.
Bajpai J; Kapu V; Rath S; Kumar S; Sekar A; Patil P; Siddiqui A; Anne S; Pawar A; Srinivas S; Bhargava P; Gulia S; Noronha V; Joshi A; Prabhash K; Banavali S; Sarin R; Badwe R; Gupta S
Lancet Oncol; 2024 Feb; 25(2):246-254. PubMed ID: 38224701
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting.
Clemons M; Dranitsaris G; Sienkiewicz M; Sehdev S; Ng T; Robinson A; Mates M; Hsu T; McGee S; Freedman O; Kumar V; Fergusson D; Hutton B; Vandermeer L; Hilton J
Breast; 2020 Dec; 54():278-285. PubMed ID: 33242754
[TBL] [Abstract][Full Text] [Related]
14. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
Nakashima K; Murakami H; Yokoyama K; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Nishiyama F; Kikugawa M; Kaneko M; Iwamoto Y; Koizumi S; Mori K; Isobe T; Takahashi T
Jpn J Clin Oncol; 2017 Sep; 47(9):840-843. PubMed ID: 28633504
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial.
Navari RM; Pywell CM; Le-Rademacher JG; White P; Dodge AB; Albany C; Loprinzi CL
JAMA Oncol; 2020 Jun; 6(6):895-899. PubMed ID: 32379269
[TBL] [Abstract][Full Text] [Related]
17. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
Rugo HS; Bianchini G; Cortes J; Henning JW; Untch M
ESMO Open; 2022 Aug; 7(4):100553. PubMed ID: 35964548
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis.
Filetti M; Lombardi P; Giusti R; Falcone R; Scotte F; Giannarelli D; Carcagnì A; Altamura V; Scambia G; Daniele G
Cancer Treat Rev; 2023 Apr; 115():102512. PubMed ID: 36774658
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.
Mizukami N; Yamauchi M; Koike K; Watanabe A; Ichihara K; Masumori N; Yamakage M
J Pain Symptom Manage; 2014 Mar; 47(3):542-50. PubMed ID: 23856100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
